Payers and providers now expect RWE to complement trial efficacy by demonstrating effectiveness, utilization impact, and ROI ...

Formulary positioning and benefit design frequently determine utilization, as weak placement or reimbursement dynamics can ...

TrumpRx’s sevenfold formulary expansion positions a government-backed portal as a high-volume generics price aggregator rather than a dispensing pharmacy. Tariff exemptions tied to three-year ...

Supreme Court inaction leaves intact lower-court rulings rejecting takings and compelled-speech theories against “fair price” designations in Medicare price negotiation. Courts emphasized ...

Affordability pressure is driving nonadherence: 55% of Americans worry about prescription costs, and ~30% report cost-related underuse, including nonfills, dose splitting, and substitution. Prior ...

Record drug shortages (≥216 active in the US in 2025) expose limited end-to-end visibility, motivating AI-driven early risk detection and coordinated mitigation across fragmented networks.

In today’s Pharma Pulse, FDA leadership changes with Makary’s resignation, Lilly shares new Zepbound and GLP-1 data, and new study data on prior authorization reform outlook. Welcome to Pharma Pulse, ...

Seventy-five executives across manufacturers and agencies backed a unified “system of work” to reduce multi-tool fragmentation across core commercial functions, reflecting a shift from tool ...

Pharma is moving from centralized patient hub services to a “hubless hub” model, using tech-enabled, distributed access tools to improve speed and outcomes. For decades, pharmaceutical companies have ...

BIOSECURE is catalyzing structural sourcing and manufacturing shifts, prompting reassessment of legacy partnerships and ...

Will Shrank, MD, explains the main hurdles to specialty therapy access, and what will impact the market over the next few years. In the final part of Pharmaceutical Commerce’s conversation with Will ...